MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Clinical Care Options Hepatitis - HBV' source. Wed, 08 Feb 2012 18:15:37 +0100 http://www.medworm.com/index.php?rid=5629964&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Primary%2520Care%2FCCO%2520Slideset%2FOverview_Slides.aspx CCO Slideset - In this downloadable slideset, Chul S. Hyun, MD, PhD, provides an overview of hepatitis B for primary care providers. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=5629964 Wed, 25 Jan 2012 00:00:00 +0100 5629964 http://www.medworm.com/index.php?rid=5583536&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202011%2FTracks%2FHighlights%2FCME_slides.aspx Learning Module - In this CME-certified slideset, Raymond T. Chung, MD, and David R. Nelson, MD, review key studies in viral hepatitis from the 2011 American Association for the Study of Liver Diseases meeting. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=5583536 Thu, 12 Jan 2012 12:29:14 +0100 5583536 http://www.medworm.com/index.php?rid=5516082&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2011%2520JO%2520Hepatitis%2520Volume%25205%2FArticles%2FEckman_CID_2011%2FSlideset.aspx CCO Slideset - Findings suggest that screening in US populations with HBV prevalence as low as 0.3% may be cost-effective and suggest that current health policy on HBV screening may need to be reconsidered. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=5516082 Fri, 16 Dec 2011 00:00:00 +0100 5516082 http://www.medworm.com/index.php?rid=5458984&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202011%2FCCO%2520Slideset%2FAASLD_2011_Slides.aspx CCO Slideset - In this downloadable slideset, Raymond T. Chung, MD, and David R. Nelson, MD, review key studies of viral hepatitis from the 2011 annual meeting of the American Association for the Study of Liver Diseases. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=5458984 Wed, 30 Nov 2011 00:00:00 +0100 5458984 http://www.medworm.com/index.php?rid=5098754&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Tests%2FInteractive%2520Virtual%2520Presentation%2FIVP_Slides.aspx CCO Slideset - In this Downloadable Slideset, Robert G. Gish, MD, provides guidance on the optimal use of virologic and serologic tests in the diagnosis and management of hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=5098754 Fri, 05 Aug 2011 00:00:00 +0100 5098754 http://www.medworm.com/index.php?rid=5070711&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Tests%2FInteractive%2520Virtual%2520Presentation%2FIVP.aspx Resource - In this Interactive Virtual Presentation, Robert G. Gish, MD, provides case-based guidance on the optimal use of virologic and serologic tests in the diagnosis and management of hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=5070711 Mon, 25 Jul 2011 00:00:00 +0100 5070711 http://www.medworm.com/index.php?rid=4994130&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FBattling%2520HCV%2FInteractive%2520Virtual%2520Presentations%2FBaseline.aspx Resource - Watch, listen, and test your knowledge as Peter Ferenci, MD, reviews the latest information on the epidemiology of HCV, screening recommendations, and baseline predictors of response to therapy. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4994130 Wed, 29 Jun 2011 15:01:56 +0100 4994130 http://www.medworm.com/index.php?rid=4886335&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBerlin%25202011%2FTracks%2FFrom%2520Podium%2520to%2520Practice%2FEASL_EA.aspx Learning Module - In this Expert Analysis, Graham R. Foster, FRCP, PhD; Paul Y. Kwo, MD; and Stefan Zeuzem, MD, provide an in-depth review of the most clinically relevant new data presented at the 2011 EASL meeting on the management of hepatitis C and other key topics. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4886335 Tue, 31 May 2011 13:07:32 +0100 4886335 http://www.medworm.com/index.php?rid=4743004&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBerlin%25202011%2FCCO%2520Slideset%2FBerlin_2011_Slides.aspx CCO Slideset - Nezam H. Afdhal, MD, FRCPI and Paul Martin, MD, highlight key data on HCV new agents, hepatitis B, nonviral hepatitis, and advanced liver disease from the 2011 EASL meeting. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4743004 Fri, 22 Apr 2011 00:00:00 +0100 4743004 http://www.medworm.com/index.php?rid=4687305&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBerlin%25202011%2FTracks%2FFrom%2520Podium%2520to%2520Practice%2FCapsules%2F71.aspx In this study, polymorphisms near IL28B appeared to predict likelihood of response following pegIFN treatment of chronic hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4687305 Tue, 05 Apr 2011 16:42:59 +0100 4687305 http://www.medworm.com/index.php?rid=4596597&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FReijnders_JHepatol_2010%2FSlideset.aspx CCO Slideset - HBsAg decline primarily occurred in HBeAg-positive patients treated with either entecavir or peginterferon monotherapy who cleared HBeAg, whereas in HBeAg-negative patients, HBsAg decline was observed only with peginterferon monotherapy and not entecavir monotherapy. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4596597 Mon, 14 Mar 2011 00:00:00 +0100 4596597 http://www.medworm.com/index.php?rid=4575915&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FPatterson_Gut_2011%2FCapsule.aspx Capsule Summary - High rate of virologic response observed, independent of baseline lamivudine and adefovir resistance mutations (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4575915 Fri, 11 Mar 2011 00:00:00 +0100 4575915 http://www.medworm.com/index.php?rid=4562229&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FChan-APT-2010%2FSlideset.aspx CCO Slideset - Seventy-five percent of patients who attain both HBsAg ≤ 300 IU/mL and > 1 log10 IU/mL decrease in HBsAg at Month 6 expected to attain sustained response to full course of peginterferon therapy. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4562229 Mon, 07 Mar 2011 00:00:00 +0100 4562229 http://www.medworm.com/index.php?rid=4319477&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2FAASLD%2520HBV%2520Guidelines%2FInteractive%2520Case%2520Challenges%2FCase_3.aspx Case Challenge - Myron J. Tong, MD, PhD, reviews guideline recommendations and key factors to consider when managing an HBeAg-negative Chinese immigrant who is fearful of Western medicine. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4319477 Thu, 06 Jan 2011 09:40:59 +0100 4319477 http://www.medworm.com/index.php?rid=4260686&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHBV%2520Treatment%2FHBV_Treatment.aspx Learning Module - Anna S. F. Lok, MD; Patrick Marcellin, MD; and Norah Terrault, MD, MPH, discuss the potential clinical implications of the most pertinent new HBV data presented at the 2010 Annual Meeting of the American Association for the Study of Liver Diseases. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4260686 Mon, 13 Dec 2010 13:59:14 +0100 4260686 http://www.medworm.com/index.php?rid=4254678&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2FAASLD%2520HBV%2520Guidelines%2FInteractive%2520Case%2520Challenges%2FCase_2.aspx Case Challenge - Robert G. Gish, MD, discusses optimal management strategies for an HBeAg-positive woman of childbearing age. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4254678 Mon, 13 Dec 2010 11:39:48 +0100 4254678 http://www.medworm.com/index.php?rid=4226861&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2FAASLD%2520HBV%2520Guidelines%2FInteractive%2520Virtual%2520Presentations%2FIVP_2_Slides.aspx CCO Slideset - Join Nezam H. Afdhal, MD, FRCPI, as he outlines AASLD guidelines and offers practical information on treatment and monitoring of HBV-infected patients. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4226861 Thu, 02 Dec 2010 00:00:00 +0100 4226861 http://www.medworm.com/index.php?rid=4184571&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2FAASLD%2520HBV%2520Guidelines%2FInteractive%2520Virtual%2520Presentations%2FIVP_2.aspx Resource - In this Interactive Virtual Presentation, Nezam H. Afdhal, MD, FRCPI, provides an in-depth review of the most recent expert guidelines on the optimal treatment of patients with chronic HBV infection. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4184571 Wed, 17 Nov 2010 13:42:08 +0100 4184571 http://www.medworm.com/index.php?rid=4176546&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FCCO%2520Slideset%2FAASLD_2010_Highlights.aspx CCO Slideset - Robert G. Gish, MD, and Stephen A. Harrison, MD, FACP, review the most clinically relevant data from this important annual meeting. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4176546 Wed, 17 Nov 2010 00:00:00 +0100 4176546 http://www.medworm.com/index.php?rid=4156452&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2FAASLD%2520HBV%2520Guidelines%2FInteractive%2520Virtual%2520Presentations%2FIVP_1_Slides.aspx CCO Slideset - In this downloadable slideset, Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, reviews the latest guideline recommendations on HBV screening, diagnosis, and treatment candidacy. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4156452 Thu, 11 Nov 2010 00:00:00 +0100 4156452 http://www.medworm.com/index.php?rid=4156451&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FReijnders_Hepatology_2010%2FSlideset.aspx CCO Slideset - The results of a small single-center study demonstrated that nearly all patients with HBeAg seroconversion who discontinued nucleos(t)ide analogue therapy after at least 6 months of consolidation had HBV disease progression within 5 years. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4156451 Thu, 11 Nov 2010 00:00:00 +0100 4156451 http://www.medworm.com/index.php?rid=4226862&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FChang_Hepatology_2010%2FSlideset.aspx CCO Slideset - At 6 years of follow-up, most patients, including those with advanced fibrosis and cirrhosis, experienced improvement in liver histology and fibrosis with entecavir treatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4226862 Wed, 10 Nov 2010 00:00:00 +0100 4226862 http://www.medworm.com/index.php?rid=4153051&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FChang_Hepatology_2010%2FSlideset.aspx CCO Slideset - At 6 years of follow-up, most patients, including those with advanced fibrosis and cirrhosis, experienced improvement in liver histology and fibrosis with entecavir treatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4153051 Wed, 10 Nov 2010 00:00:00 +0100 4153051 http://www.medworm.com/index.php?rid=4153050&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FBerg_Hepatology_2010%2FSlideset.aspx CCO Slideset - Presence of adefovir- or lamivudine-associated resistance mutations did not predict treatment response, but patient adherence to study medication was an important factor in achieving HBV DNA suppression. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4153050 Wed, 10 Nov 2010 00:00:00 +0100 4153050 http://www.medworm.com/index.php?rid=4136068&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2FAASLD%2520HBV%2520Guidelines%2FInteractive%2520Virtual%2520Presentations%2FIVP_1.aspx Resource - Watch, listen, and test your knowledge as Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, reviews the latest guideline recommendations on screening for and diagnosing hepatitis B virus infection and determining the need for treatment and/or follow-up after diagnosis. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4136068 Fri, 05 Nov 2010 09:02:22 +0100 4136068 http://www.medworm.com/index.php?rid=4136069&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHBV%2520Treatment%2FCapsules%2F212.aspx Capsule Summary - Telbivudine use in highly viremic HBeAg-positive mothers during Weeks 20-32 of pregnancy significantly reduces HBV DNA in mothers by time of delivery. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4136069 Thu, 04 Nov 2010 11:46:24 +0100 4136069 http://www.medworm.com/index.php?rid=4136070&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHBV%2520Treatment%2FCapsules%2F235.aspx Capsule Summary - All newborns with immunoprophylaxis failure born to mothers with high serum HBV DNA levels. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4136070 Thu, 04 Nov 2010 11:12:54 +0100 4136070 http://www.medworm.com/index.php?rid=4136071&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHBV%2520Treatment%2FCapsules%2F215.aspx Capsule Summary - Trend consistent across groups stratified by baseline ALT level and virus genotype. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4136071 Wed, 03 Nov 2010 17:55:28 +0100 4136071 http://www.medworm.com/index.php?rid=4128013&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHBV%2520Treatment%2FCapsules%2F133.aspx Capsule Summary - Extending duration of pegIFN in patients with HBeAg-positive chronic HBV infection from 24 to 48 weeks improved efficacy, but increasing the dose from 1.0 to 1.5 µg/kg/week for 24 weeks did not. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4128013 Tue, 02 Nov 2010 16:38:39 +0100 4128013 http://www.medworm.com/index.php?rid=4128014&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHBV%2520Treatment%2FCapsules%2F175.aspx Capsule Summary - Severe liver disease outcomes correlates with older age, male sex, race, and documented alcohol abuse in patients with chronic HBV infection. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4128014 Tue, 02 Nov 2010 16:37:26 +0100 4128014 http://www.medworm.com/index.php?rid=4128015&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHBV%2520Treatment%2FCapsules%2F135.aspx Capsule Summary - Rates of dose modification, treatment discontinuation, treatment-related adverse events, and laboratory abnormalities were similar with 48 vs 96 weeks of therapy. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4128015 Tue, 02 Nov 2010 12:48:29 +0100 4128015 http://www.medworm.com/index.php?rid=4128016&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHBV%2520Treatment%2FCapsules%2F477.aspx Capsule Summary - HBeAg and HBsAg loss and seroconversion continued to occur through 4 years of tenofovir treatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4128016 Mon, 01 Nov 2010 11:42:17 +0100 4128016 http://www.medworm.com/index.php?rid=4226863&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FChang_Hepatology_2010%2FCapsule.aspx Capsule Summary - At 6 years of follow-up, most patients, including those with advanced fibrosis and cirrhosis, experienced improvement in liver histology and fibrosis with entecavir treatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4226863 Fri, 29 Oct 2010 00:00:00 +0100 4226863 http://www.medworm.com/index.php?rid=4120652&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FChang_Hepatology_2010%2FCapsule.aspx Capsule Summary - At 6 years of follow-up, most patients, including those with advanced fibrosis and cirrhosis, experienced improvement in liver histology and fibrosis with entecavir treatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4120652 Fri, 29 Oct 2010 00:00:00 +0100 4120652 http://www.medworm.com/index.php?rid=4111032&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2FAASLD%2520HBV%2520Guidelines%2FInteractive%2520Case%2520Challenges%2FCase_1.aspx Case Challenge - Robert J. Fontana, MD, discusses the challenging management decisions involved in treating an HBV-infected patient with decompensated cirrhosis. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4111032 Thu, 28 Oct 2010 10:04:21 +0100 4111032 http://www.medworm.com/index.php?rid=4111033&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FBerg_Hepatology_2010%2FCapsule.aspx Capsule Summary - Presence of adefovir- or lamivudine-associated resistance mutations did not predict treatment response, but patient adherence to study medication was an important factor in achieving HBV DNA suppression. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4111033 Wed, 27 Oct 2010 00:00:00 +0100 4111033 http://www.medworm.com/index.php?rid=4006206&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520and%2520HCC%2FInteractive%2520Virtual%2520Presentation%2FIVP.aspx Resource - In this Interactive Virtual Presentation, Steven-Huy Han, MD, AGAF, provides a case-based overview of the relationship between HBV and HCC including recommended HCC surveillance, staging, and treatment strategies. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=4006206 Tue, 28 Sep 2010 00:00:00 +0100 4006206 http://www.medworm.com/index.php?rid=3913790&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal+Options%2FCollections%2F2010+JO+Hepatitis+Volume+4%2FArticles%2FWong_Hepatology_2010%2FCapsule.aspx Capsule Summary - Virologic response at end of treatment found to be strongest independent predictor of sustained virologic response at 5 years posttreatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3913790 Thu, 12 Aug 2010 00:00:00 +0100 3913790 http://www.medworm.com/index.php?rid=3913789&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal+Options%2FCollections%2F2010+JO+Hepatitis+Volume+4%2FArticles%2FJung-JCG-2009%2FSlideset.aspx CCO Slideset - Decline in HBsAg correlated with decline in HBV DNA through 1 year of entecavir treatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3913789 Thu, 12 Aug 2010 00:00:00 +0100 3913789 http://www.medworm.com/index.php?rid=3913788&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal+Options%2FCollections%2F2010+JO+Hepatitis+Volume+4%2FArticles%2FWong_Hepatology_2010%2FSlideset.aspx CCO Slideset - Virologic response at end of treatment found to be strongest independent predictor of SVR at 5 years posttreatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3913788 Thu, 12 Aug 2010 00:00:00 +0100 3913788 http://www.medworm.com/index.php?rid=3913787&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal+Options%2FCollections%2F2010+JO+Hepatitis+Volume+4%2FArticles%2FVan_Bommel-Hepatology-2010%2FSlideset.aspx CCO Slideset - Tenofovir well tolerated in patients with previous nucleos(t)ide analogue failure. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3913787 Thu, 12 Aug 2010 00:00:00 +0100 3913787 http://www.medworm.com/index.php?rid=3860028&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FWong_Hepatology_2010%2FCapsule.aspx Capsule Summary - Virologic response at end of treatment found to be strongest independent predictor of sustained virologic response at 5 years posttreatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3860028 Thu, 12 Aug 2010 00:00:00 +0100 3860028 http://www.medworm.com/index.php?rid=3860027&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FJung-JCG-2009%2FSlideset.aspx CCO Slideset - Decline in HBsAg correlated with decline in HBV DNA through 1 year of entecavir treatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3860027 Thu, 12 Aug 2010 00:00:00 +0100 3860027 http://www.medworm.com/index.php?rid=3860026&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FWong_Hepatology_2010%2FSlideset.aspx CCO Slideset - Virologic response at end of treatment found to be strongest independent predictor of SVR at 5 years posttreatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3860026 Thu, 12 Aug 2010 00:00:00 +0100 3860026 http://www.medworm.com/index.php?rid=3860025&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FVan_Bommel-Hepatology-2010%2FSlideset.aspx CCO Slideset - Tenofovir well tolerated in patients with previous nucleos(t)ide analogue failure. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3860025 Thu, 12 Aug 2010 00:00:00 +0100 3860025 http://www.medworm.com/index.php?rid=3913792&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal+Options%2FCollections%2F2010+JO+Hepatitis+Volume+4%2FArticles%2FJung-JCG-2009%2FCapsule.aspx Capsule Summary - Decline in HBsAg correlated with decline in HBV DNA through 1 year of entecavir treatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3913792 Thu, 05 Aug 2010 00:00:00 +0100 3913792 http://www.medworm.com/index.php?rid=3788429&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment+Updates%2FStay+Tuned+1%2FVolume+1+Edition+2%2FReference+Material%2FMin_Slides.aspx CCO Slideset - A concise slideset detailing potential cultural barriers to screening and treatment among Asian Americans. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788429 Thu, 15 Jul 2010 00:00:00 +0100 3788429 http://www.medworm.com/index.php?rid=3788430&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FVienna+2010%2FVirtual+Presentation+Programs%2FHighlights%2FExpert_Recap.aspx CCO Expert Recap - In collaboration with Alfredo Alberti, MD, Paul Martin, MD, presents the most clinically relevant data on viral hepatitis and advanced liver disease from the 2010 meeting in Vienna. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788430 Wed, 09 Jun 2010 19:05:32 +0100 3788430 http://www.medworm.com/index.php?rid=3788432&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment+Updates%2FAdherence%2FInteractive+Virtual+Presentation%2FAdherence.aspx CCO Slideset - Robert G. Gish, MD, highlights the challenges for maintaining adherence in hepatitis B patients, and strategies for overcoming these barriers. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788432 Wed, 12 May 2010 12:00:00 +0100 3788432 http://www.medworm.com/index.php?rid=3788431&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment+Updates%2FAdherence%2FInteractive+Virtual+Presentation%2FAdherence_iVp.aspx Resource - In this Interactive Virtual Presentation, Robert G. Gish, MD, discusses the challenges in maintaining adherence to HBV therapy and strategies for overcoming these barriers. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788431 Wed, 12 May 2010 12:00:00 +0100 3788431 http://www.medworm.com/index.php?rid=3558054&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FAdherence%2FInteractive%2520Virtual%2520Presentation%2FAdherence.aspx CCO Slideset - Robert G. Gish, MD, highlights the challenges for maintaining adherence in hepatitis B patients, and strategies for overcoming these barriers. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3558054 Wed, 12 May 2010 12:00:00 +0100 3558054 http://www.medworm.com/index.php?rid=3558053&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FAdherence%2FInteractive%2520Virtual%2520Presentation%2FAdherence_iVp.aspx Resource - In this Interactive Virtual Presentation, Robert G. Gish, MD, discusses the challenges in maintaining adherence to HBV therapy and strategies for overcoming these barriers. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3558053 Wed, 12 May 2010 12:00:00 +0100 3558053 http://www.medworm.com/index.php?rid=3788433&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FVienna+2010%2FCCO+Slideset%2FHighlights.aspx CCO Slideset - In this downloadable slideset, Alfredo Alberti, MD, and Paul Martin, MD, highlight key data in HCV, HBV, and advanced liver disease from the 2010 meeting in Vienna. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788433 Mon, 03 May 2010 12:00:00 +0100 3788433 http://www.medworm.com/index.php?rid=3788434&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FVienna+2010%2FTracks%2FOther+Topics%2FCapsules%2F1017.aspx Capsule Summary - Tenofovir activity observed regardless of presence of adefovir or lamivudine resistance mutations. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788434 Mon, 19 Apr 2010 16:51:40 +0100 3788434 http://www.medworm.com/index.php?rid=3484560&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FVienna%25202010%2FTracks%2FOther%2520Topics%2FCapsules%2F1017.aspx Capsule Summary - Tenofovir activity observed regardless of presence of adefovir or lamivudine resistance mutations. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3484560 Mon, 19 Apr 2010 16:51:40 +0100 3484560 http://www.medworm.com/index.php?rid=3788435&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FVienna+2010%2FTracks%2FOther+Topics%2FCapsules%2F1011.aspx Capsule Summary - Genotype B/C HBV predictive for development of HCC in univariate analysis. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788435 Mon, 19 Apr 2010 12:21:42 +0100 3788435 http://www.medworm.com/index.php?rid=3788436&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FVienna+2010%2FTracks%2FOther+Topics%2FCapsules%2F98.aspx Capsule Summary - Virologic response rate at 1 year posttreatment was significantly higher for patients treated with pegIFN for 96 vs 48 weeks (29% vs 12%; P = .03). (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788436 Sun, 18 Apr 2010 15:06:17 +0100 3788436 http://www.medworm.com/index.php?rid=3788437&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FVienna+2010%2FTracks%2FOther+Topics%2FCapsules%2F8.aspx Capsule Summary - While HBsAg and HBV DNA levels both predict sustained response to peginterferon treatment in HBeAg-negative chronic hepatitis B patients at various time points, combination on-treatment decline allows definitive stopping rule. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788437 Sat, 17 Apr 2010 12:00:00 +0100 3788437 http://www.medworm.com/index.php?rid=3788438&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FVienna+2010%2FTracks%2FOther+Topics%2FCapsules%2F28.aspx Capsule Summary - Favorable safety profile with emtricitabine/tenofovir when used for prevention of HBV recurrence post–orthotopic liver transplantation; renal function preserved. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788438 Sat, 17 Apr 2010 10:17:46 +0100 3788438 http://www.medworm.com/index.php?rid=3788439&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FVienna+2010%2FTracks%2FOther+Topics%2FCapsules%2F7.aspx Capsule Summary - Trend toward greater HBV DNA reduction, higher rate of ALT normalization, fewer viral breakthroughs, and improved renal function with telbivudine vs lamivudine. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788439 Sat, 17 Apr 2010 09:27:19 +0100 3788439 http://www.medworm.com/index.php?rid=3788440&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FVienna+2010%2FTracks%2FHCV%2FCapsules%2F37.aspx Capsule Summary - SVR rate among previous genotype 2/3 HCV nonresponders or relapsers retreated with RG7128 plus PegIFN/RBV twice as high as rates typically observed with standard PegIFN/RBV retreatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788440 Wed, 14 Apr 2010 00:00:00 +0100 3788440 http://www.medworm.com/index.php?rid=3001609&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202009%2FCCO%2520Slideset%2FAASLD_2009_Highlights.aspx CCO Slideset - Review the most clinically relevant new data from the 2009 AASLD conference on HCV, HBV, and complications of advanced liver disease. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3001609 Tue, 17 Nov 2009 00:00:00 +0100 3001609 http://www.medworm.com/index.php?rid=3788441&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FManagement+of+HBV%2FCapsules%2F222.aspx Capsule Summary - The safety profile and virologic, biochemical, and clinical efficacy outcomes were similar among patients treated with 48 weeks of tenofovir/emtricitabine, tenofovir monotherapy, or entecavir monotherapy in this randomized phase II study. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788441 Thu, 05 Nov 2009 16:48:00 +0100 3788441 http://www.medworm.com/index.php?rid=3788442&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment+Updates%2FHBV+Iceberg%2FCCO+Slideset%2FHBV_Iceberg_Slides.aspx CCO Slideset - Downloadable slides for use in your own noncommercial presentations highlight key data on selecting patients for HBV screening and evaluation and optimizing first-line treatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788442 Thu, 05 Nov 2009 16:13:03 +0100 3788442 http://www.medworm.com/index.php?rid=2956491&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202009%2FTracks%2FManagement%2520of%2520HBV%2FCapsules%2F137.aspx Capsule Summary - A multivariate analysis identified cirrhosis, older age, and male sex as independent predictors of hepatocellular carcinoma incidence in patients receiving at least 12 months of oral antiviral therapy, most of which was lamivudine based. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2956491 Tue, 03 Nov 2009 12:00:00 +0100 2956491 http://www.medworm.com/index.php?rid=3788443&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FManagement+of+HBV%2FCapsules%2F486.aspx Capsule Summary - Intrahepatic cccDNA levels at baseline were not prognostic for response to peginterferon alfa-2a plus adefovir therapy. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788443 Mon, 02 Nov 2009 17:23:09 +0100 3788443 http://www.medworm.com/index.php?rid=3788444&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FManagement+of+HBV%2FCapsules%2F476.aspx Capsule Summary - Virologic response rates with entecavir were highest among patients who were previously untreated and among those with HBeAg-negative disease or low baseline HBV DNA levels; high response rates were also observed among patients with precore mutations. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788444 Mon, 02 Nov 2009 09:01:53 +0100 3788444 http://www.medworm.com/index.php?rid=3788446&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal+Options%2FCollections%2F2009+JO+Hepatitis+Volume+3%2FArticles%2FTai-Hepatology-2009%2FSlideset.aspx CCO Slideset - In this long-term follow-up study, higher maximal ALT level during follow-up of a mean of 13 years was associated with increased risk of development of cirrhosis and liver-related mortality among HBeAg-negative, HBsAg-positive individuals. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788446 Tue, 27 Oct 2009 00:00:00 +0100 3788446 http://www.medworm.com/index.php?rid=3788445&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal+Options%2FCollections%2F2009+JO+Hepatitis+Volume+3%2FArticles%2FBuster-AJG-2009%2FSlideset.aspx CCO Slideset - More than one third of patients with HBeAg loss within the first 32 weeks of therapy with peginterferon alfa-2b alone or in combination with lamivudine were negative for HBsAg at long-term follow-up 3 years later. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3788445 Tue, 27 Oct 2009 00:00:00 +0100 3788445 http://www.medworm.com/index.php?rid=3668408&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2009%2520JO%2520Hepatitis%2520Volume%25203%2FArticles%2FTai-Hepatology-2009%2FSlideset.aspx CCO Slideset - In this long-term follow-up study, higher maximal ALT level during follow-up of a mean of 13 years was associated with increased risk of development of cirrhosis and liver-related mortality among HBeAg-negative, HBsAg-positive individuals. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3668408 Tue, 27 Oct 2009 00:00:00 +0100 3668408 http://www.medworm.com/index.php?rid=3668407&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2009%2520JO%2520Hepatitis%2520Volume%25203%2FArticles%2FBuster-AJG-2009%2FSlideset.aspx CCO Slideset - More than one third of patients with HBeAg loss within the first 32 weeks of therapy with peginterferon alfa-2b alone or in combination with lamivudine were negative for HBsAg at long-term follow-up 3 years later. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=3668407 Tue, 27 Oct 2009 00:00:00 +0100 3668407 http://www.medworm.com/index.php?rid=2932590&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FTai-Hepatology-2009%2FSlideset.aspx CCO Slideset - In this long-term follow-up study, higher maximal ALT level during follow-up of a mean of 13 years was associated with increased risk of development of cirrhosis and liver-related mortality among HBeAg-negative, HBsAg-positive individuals. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2932590 Tue, 27 Oct 2009 00:00:00 +0100 2932590 http://www.medworm.com/index.php?rid=2932589&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FBuster-AJG-2009%2FSlideset.aspx CCO Slideset - More than one third of patients with HBeAg loss within the first 32 weeks of therapy with peginterferon alfa-2b alone or in combination with lamivudine were negative for HBsAg at long-term follow-up 3 years later. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2932589 Tue, 27 Oct 2009 00:00:00 +0100 2932589 http://www.medworm.com/index.php?rid=2900520&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FTai-Hepatology-2009%2FCapsule.aspx Capsule Summary - In this long-term follow-up study, higher maximal ALT level during follow-up of a mean of 13 years was associated with increased risk of development of cirrhosis and liver-related mortality among HBeAg-negative, HBsAg-positive individuals. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2900520 Thu, 15 Oct 2009 00:00:00 +0100 2900520 http://www.medworm.com/index.php?rid=2676360&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2009%2520Annual%2520Update%2FModules%2FDusheiko.aspx Learning Module - Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, reviews the benefits and risks of hepatitis B management using currently available therapeutic agents. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2676360 Fri, 31 Jul 2009 19:40:31 +0100 2676360 http://www.medworm.com/index.php?rid=2659236&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2009%2520Annual%2520Update%2FModules%2FDusheiko.aspx Learning Module - Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, reviews the benefits and risks of hepatitis B management using currently available therapeutic agents. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2659236 Fri, 31 Jul 2009 19:40:31 +0100 2659236 http://www.medworm.com/index.php?rid=2589928&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2009%2520Annual%2520Update%2FModules%2FLok.aspx Learning Module - Anna S. F. Lok, MD, discusses factors to consider when evaluating patients with chronic hepatitis B infection for initiating treatment. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2589928 Fri, 10 Jul 2009 12:00:00 +0100 2589928 http://www.medworm.com/index.php?rid=2518734&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FHBV.aspx Learning Module - Join Maria Buti, MD; Anna S. F. Lok, MD; and Patrick Marcellin, MD, as they review and discuss the latest data on the treatment of chronic HBV infection presented at the 2009 European Association for the Study of the Liver annual meeting. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2518734 Wed, 17 Jun 2009 09:44:30 +0100 2518734 http://www.medworm.com/index.php?rid=2470645&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FInitial%2520HBV%2520Treatment%2FInteractive%2520Case%2520Challenges%2FPan%2520Case.aspx Case Challenge - Attempt this Interactive Case Challenge and learn strategies for frontline regimen selection and on-treatment management of patients with HBeAg-negative chronic HBV infection with Calvin Q. Pan, MD, FACP, FACG. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2470645 Tue, 09 Jun 2009 12:00:00 +0100 2470645 http://www.medworm.com/index.php?rid=2444254&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FInitial%2520HBV%2520Treatment%2FModule%2FGish%2520Module.aspx Learning Module - Robert G. Gish, MD, describes the latest data and reviews the most recent guidelines on the optimal selection of first-line therapy for patients with chronic hepatitis B infection. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2444254 Fri, 29 May 2009 15:39:36 +0100 2444254 http://www.medworm.com/index.php?rid=2444257&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FMarcellin-NEJM-2008%2FSlideset.aspx CCO Slideset - In 2 randomized trials, HBeAg-positive and HBeAg-negative patients receiving tenofovir for 48 weeks achieved higher rates of HBV DNA suppression vs adefovir and significantly more HBeAg-positive patients achieved ALT normalization and HBsAg loss with tenofovir vs adefovir. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2444257 Thu, 28 May 2009 00:00:00 +0100 2444257 http://www.medworm.com/index.php?rid=2444256&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FInitial%2520HBV%2520Treatment%2FInteractive%2520Case%2520Challenges%2FMin%2520Case.aspx Case Challenge - Learn about frontline regimen selection and on-treatment management of an HBeAg-positive patient and apply this learning with Albert D. Min, MD, in this Interactive Case Challenge. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2444256 Thu, 28 May 2009 00:00:00 +0100 2444256 http://www.medworm.com/index.php?rid=2444258&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FMarcellin-NEJM-2008%2FCapsule.aspx Capsule Summary - In 2 randomized trials, HBeAg-positive and HBeAg-negative patients receiving tenofovir for 48 weeks achieved higher rates of HBV DNA suppression vs adefovir and significantly more HBeAg-positive patients achieved ALT normalization and HBsAg loss with tenofovir vs adefovir. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2444258 Wed, 27 May 2009 14:54:34 +0100 2444258 http://www.medworm.com/index.php?rid=2400576&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FMoucari-Hepatology-2008%2FSlideset.aspx CCO Slideset - In a prospective study, > 0.5 log10 IU/mL decrease in HBsAg at Week 12 or > 1.0 log10 IU/mL decrease at Week 24 had high predictive value for subsequent SVR in HBeAg-negative patients treated with peginterferon alfa-2a. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2400576 Thu, 07 May 2009 00:00:00 +0100 2400576 http://www.medworm.com/index.php?rid=2371287&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F903.aspx Capsule Summary - Baseline adefovir and lamivudine resistance mutations did not impair subsequent Week 96 response to tenofovir +/- emtricitabine. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2371287 Sun, 26 Apr 2009 14:09:21 +0100 2371287 http://www.medworm.com/index.php?rid=2371288&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F911.aspx Capsule Summary - Undetectable HBV DNA at treatment Week 24 associated with improved long-term (3 years) virologic, biochemical, and serologic outcomes vs patients with detectable Week 24 HBV DNA. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2371288 Sun, 26 Apr 2009 10:29:40 +0100 2371288 http://www.medworm.com/index.php?rid=2371289&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F907.aspx Capsule Summary - Combination of peginterferon alfa-2a and telbivudine not recommended due to increased rates of peripheral neuropathy. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2371289 Sun, 26 Apr 2009 09:04:39 +0100 2371289 http://www.medworm.com/index.php?rid=2366331&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F21.aspx Capsule Summary - Virologic, biochemical, and immunologic response rates were statistically similar among cirrhotic vs noncirrhotic patients treated with 96 weeks of tenofovir. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2366331 Fri, 24 Apr 2009 16:01:20 +0100 2366331 http://www.medworm.com/index.php?rid=2366332&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F20.aspx Capsule Summary - Entecavir resistance rare in treatment-naive patients but common at Year 6 in patients with lamivudine-refractory HBV. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2366332 Fri, 24 Apr 2009 15:33:27 +0100 2366332 http://www.medworm.com/index.php?rid=2518735&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F1040.aspx Capsule Summary - A higher rate of seroprotection was achieved with the HBsAg-1018 immunostimulatory sequence vs the standard HBV vaccine, even among participants aged 40-55 years. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2518735 Fri, 17 Apr 2009 00:00:00 +0100 2518735 http://www.medworm.com/index.php?rid=2366336&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F17.aspx Capsule Summary - Rapid HBsAg decline during the first year of telbivudine therapy predictive of a high rate of HBsAg clearance at Year 3. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2366336 Fri, 17 Apr 2009 00:00:00 +0100 2366336 http://www.medworm.com/index.php?rid=2366335&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F18.aspx Capsule Summary - More than one half of HBeAg-negative patients sustained response to long-term adefovir therapy for > 4 years after treatment discontinuation. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2366335 Fri, 17 Apr 2009 00:00:00 +0100 2366335 http://www.medworm.com/index.php?rid=2366334&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F3.aspx Capsule Summary - Birth defect rates were similar with first vs second/third trimester exposure to antiretrovirals in the Antiretroviral Pregnancy Registry cohort. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2366334 Fri, 17 Apr 2009 00:00:00 +0100 2366334 http://www.medworm.com/index.php?rid=2366333&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FCopenhagen%25202009%2FTracks%2FHBV%2520Treatment%2FCapsules%2F19.aspx Capsule Summary - Virologic response rate to entecavir significantly lower in patients with lamivudine resistance vs those without. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2366333 Fri, 17 Apr 2009 00:00:00 +0100 2366333 http://www.medworm.com/index.php?rid=2252256&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FNormal%2520ALT%2FInteractive%2520Virtual%2520Presentation%2FALT%2520%2C-a-%2C%2520Hepatitis%2520B.aspx CCO Virtual Presentation - W. Ray Kim, MD, discusses the importance of ALT in hepatitis B and outlines management approaches for patients with normal ALT levels. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2252256 Fri, 06 Mar 2009 00:00:00 +0100 2252256 http://www.medworm.com/index.php?rid=2252257&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FPreventing%2520HBV%2520Resistance%2FModules%2FPreventing%2520Resistance.aspx Learning Module - Marc G. Ghany, MD, discusses oral agents for the treatment of chronic hepatitis B, their potency, and barriers to resistance and how this impacts the selection of initial treatment regimens. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2252257 Thu, 05 Mar 2009 12:00:00 +0100 2252257 http://www.medworm.com/index.php?rid=2171601&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Nonresponders%2FSlideset%2520Module%2FSlideset%2520Module.aspx Learning Module - Mitchell L. Shiffman, MD, reviews the various types of virologic response in patients treated for hepatitis C virus infection, discusses what factors are associated with better responses, and summarizes the most recent data available on various retreatment strategies. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2171601 Mon, 09 Feb 2009 00:00:00 +0100 2171601 http://www.medworm.com/index.php?rid=2171600&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Resistance%2FModules%2FZoulim.aspx Learning Module - Dr. Fabien Zoulim describes assays for HBV drug resistance. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2171600 Mon, 09 Feb 2009 00:00:00 +0100 2171600 http://www.medworm.com/index.php?rid=2171599&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2007%2520Annual%2520Update%2FModules%2FLok.aspx Learning Module - Anna S. F. Lok, MD, discusses the definitions, consequences of, and treatment strategies for HBV drug resistance. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2171599 Mon, 09 Feb 2009 00:00:00 +0100 2171599 http://www.medworm.com/index.php?rid=2171598&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Case%2520Debates%2FInteractive%2520Case%2520Challenges%2FTreatment-naive.aspx Case Challenge - Jules L. Dienstag, MD, reviews the factors involved in selecting the optimal treatment in patients seeking first-line therapy for hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2171598 Mon, 09 Feb 2009 00:00:00 +0100 2171598 http://www.medworm.com/index.php?rid=2171597&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2008%2520Annual%2520Update%2FModules%2FHerrera.aspx Learning Module - Jorge L. Herrera, MD, reviews the top hepatology articles from the past year and reviews their applications for clinical practice. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2171597 Mon, 09 Feb 2009 00:00:00 +0100 2171597 http://www.medworm.com/index.php?rid=2171596&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Tools%2FInteractive%2520Case%2520Challenges%2FTreatment%2520Naive%2520ICC.aspx Case Challenge - Robert G. Gish, MD, reviews the importance of HBV DNA in determining treatment candidacy and making on-treatment decisions in hepatitis B management in this interactive case challenge. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2171596 Mon, 09 Feb 2009 00:00:00 +0100 2171596 http://www.medworm.com/index.php?rid=2171595&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520and%2520Depression%25202008%2FInteractive%2520Case%2520Challenges%2FAlberti%2520Case.aspx Case Challenge - Join Alfredo Alberti, MD, in choosing the optimal treatment strategies for a woman who develops depressive symptoms during HCV therapy, despite the absence of symptoms at treatment baseline. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2171595 Mon, 09 Feb 2009 00:00:00 +0100 2171595 http://www.medworm.com/index.php?rid=2171594&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FManagement%2520Series%2FFirst-Line%2520Therapy%2FModule%2FFirst-Line%2520Choices.aspx Learning Module - Kris V. Kowdley, MD, FACP, discusses the determinants for treatment candidacy, the goals of HBV therapy, and factors for selecting first-line treatment in hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2171594 Mon, 09 Feb 2009 00:00:00 +0100 2171594 http://www.medworm.com/index.php?rid=2140347&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FPreventing%2520HBV%2520Resistance%2FModules%2FMechanisms%2520of%2520Resistance.aspx Learning Module - Maria Buti, MD, reviews the development of HBV antiviral resistance in context of the life cycle of HBV and the mechanisms of action of antiviral drugs. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2140347 Wed, 28 Jan 2009 12:00:00 +0100 2140347 http://www.medworm.com/index.php?rid=2109712&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FCCO%2520Slideset%2FHBV%2520Highlights.aspx CCO Slideset - This downloadable slideset reviews key hepatitis B data from the 2008 AASLD meeting and shows how these data relate to the current management of hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2109712 Wed, 14 Jan 2009 00:00:00 +0100 2109712 http://www.medworm.com/index.php?rid=2080110&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FInvestigational%2520HBV%2520and%2520HCV%2520Agents%2FInvestigational%2520HBV%2520and%2520HCV%2520Agents.aspx Learning Module - Join Nezam H. Afdhal, MD, FRCPI; Fred Poordad, MD; and Stefan Zeuzem, MD, as they discuss novel agents being developed for the treatment of chronic HBV and HCV infections. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2080110 Mon, 05 Jan 2009 00:00:00 +0100 2080110 http://www.medworm.com/index.php?rid=2080111&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FVirtual%2520Presentation%2520Programs%2FHBV%2FHBV%2520ER.aspx CCO Expert Recap - Watch and listen as Nezam H. Afdhal, MD, FRCPI, reviews the key clinical data on hepatitis B investigational and approved agents presented at the 2008 AASLD meeting. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2080111 Fri, 02 Jan 2009 00:00:00 +0100 2080111 http://www.medworm.com/index.php?rid=2050817&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FTracks%2FApproved%2520HBV%2520Agents%2FApproved%2520HBV%2520Agents.aspx Learning Module - Join Jules L. Dienstag, MD; Robert G. Gish, MD; and Ira M. Jacobson, MD, as they discuss data presented at the 2008 AASLD Meeting on advances in the use of currently approved therapies for the treatment of chronic hepatitis B infection. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2050817 Wed, 17 Dec 2008 00:00:00 +0100 2050817 http://www.medworm.com/index.php?rid=2038312&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FBuster-Gastroenterol-2008%2FSlideset.aspx CCO Slideset - Long-term follow-up demonstrates sustained HBeAg negativity with high rate of HBsAg loss following peginterferon alfa-2b therapy; genotype A HBV associated with significantly higher rate of HBsAg loss. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2038312 Tue, 16 Dec 2008 00:00:00 +0100 2038312 http://www.medworm.com/index.php?rid=2038313&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FArticles%2FBuster-Gastroenterol-2008%2FCapsule.aspx Capsule Summary - Long-term follow-up demonstrates sustained HBeAg negativity with high rate of HBsAg loss following peginterferon alfa-2b therapy; genotype A HBV associated with significantly higher rate of HBsAg loss. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2038313 Mon, 15 Dec 2008 00:00:00 +0100 2038313 http://www.medworm.com/index.php?rid=2031558&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Prime%2520Time%2FInteractive%2520Virtual%2520Presentations%2FHBV%2520Patient%2520Populations.aspx CCO Virtual Presentation - Join Heiner Wedemeyer, MD, as he reviews HBV infection management in the setting of pregnancy and potential pregnancy. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2031558 Fri, 12 Dec 2008 16:06:03 +0100 2031558 http://www.medworm.com/index.php?rid=2031559&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Prime%2520Time%2FInteractive%2520Virtual%2520Presentations%2FEfficacy%2C%2520Resistance%2C%2520and%2520Durability.aspx CCO Virtual Presentation - Join Stephen Locarnini, MD, PhD, FRC (Path), as he discusses current concepts on how to best avoid antiviral resistance to initial HBV therapies. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2031559 Thu, 11 Dec 2008 12:00:00 +0100 2031559 http://www.medworm.com/index.php?rid=2031560&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Prime%2520Time%2FInteractive%2520Virtual%2520Presentations%2FManagement%2520of%2520Suboptimal%2520Response.aspx CCO Virtual Presentation - Join Ching-Lung Lai, MD, as he reviews strategies to identify and manage incomplete response in HBV-infected patients receiving treatment with oral antiviral therapies. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2031560 Wed, 10 Dec 2008 12:00:00 +0100 2031560 http://www.medworm.com/index.php?rid=2020801&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202008%2FVirtual%2520Presentation%2520Programs%2FHBV%2FHBV%2520Slides.aspx CCO Slideset - This downloadable slideset reviews the most clinically relevant new data on hepatitis B approved and investigational therapies presented at the 2008 American Association for the Study of Liver Diseases Meeting. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=2020801 Wed, 19 Nov 2008 08:47:06 +0100 2020801 http://www.medworm.com/index.php?rid=1954410&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2008%2520Annual%2520Update%2FModules%2FGhany.aspx Marc G. Ghany, MD, discusses cccDNA and its role in the difficult path of obtaining a true cure for HBV infection. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1954410 Thu, 13 Nov 2008 08:38:20 +0100 1954410 http://www.medworm.com/index.php?rid=1917126&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2008%2520Annual%2520Update%2FModules%2FGarcia-Tsao.aspx Guadalupe Garcia-Tsao, MD, reviews strategies for managing the clinical complications of cirrhosis. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1917126 Thu, 30 Oct 2008 07:59:04 +0100 1917126 http://www.medworm.com/index.php?rid=1899511&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FAnnual%2520Updates%2F2008%2520Annual%2520Update%2FModules%2FLok.aspx Anna S. F. Lok, MD, discusses factors to consider when screening patients with chronic hepatitis B infection for treatment initiation. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1899511 Fri, 24 Oct 2008 08:36:28 +0100 1899511 http://www.medworm.com/index.php?rid=1814509&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FMilan%25202008%2FVirtual%2520Presentation%2520Programs%2FHepatitis%2520B%2520ER.aspx Daniel Shouval, MD, provides an update on the latest management strategies for patients with chronic hepatitis B. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1814509 Tue, 23 Sep 2008 08:23:23 +0100 1814509 http://www.medworm.com/index.php?rid=1540857&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520Election.aspx Tram T. Tran, MD, and Robert S. Brown, Jr., MD, MPH, discuss new agents for the treatment of chronic hepatitis B and how they might fit in the treatment landscape. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1540857 Wed, 25 Jun 2008 20:28:27 +0100 1540857 http://www.medworm.com/index.php?rid=1435721&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FMilan%25202008%2FTracks%2FHepatitis%2520B%2FCapsules%2F57.aspx Study 102 illustrated that viral suppression as a result of tenofovir therapy is sustained over 72 weeks without the emergence of resistance (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1435721 Mon, 12 May 2008 23:04:46 +0100 1435721 http://www.medworm.com/index.php?rid=1364425&cid=s_33082_20_f&fid=33082&url=http%3A%2F%2Fclinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHBV%2520On%2520Treatment%2FVirtual%2520Presentation%2FPresentation.aspx Join Ira M. Jacobson, MD, as he reviews on-treatment HBV guidelines including the relationships between early responses to oral anti-HBV agents and future treatment outcomes. (Source: Clinical Care Options Hepatitis - HBV) Clinical Care Options Hepatitis - HBV journals http://www.medworm.com/rss/comments.php?id=1364425 Fri, 11 Apr 2008 07:00:32 +0100 1364425